Skip to Content


Filter by:



Second Opinion

Learn about policy issues important to medical schools and teaching hospitals, with Executive Vice President Atul Grover, M.D., Ph.D.

Washington Highlights

AAMC Opposes Genentech’s Use of Specialty Distributors for Certain Cancer Drugs

October 31, 2014—The AAMC Oct. 27 joined five other hospital associations in sending a letter  to Genentech, Inc. CEO Ian T. Clark, urging the reversal of a recent and “misguided decision” to transition three cancer drugs (Avastin, Herceptin, and Rituxan) from traditional to specialty distributors.

The letter expresses concerns that such action would potentially undermine patient care by delaying therapies, eliminate discounts and other price reductions typically offered by traditional distributors, present significant data and reporting challenges, and possibly trigger unintended consequences such as counterfeiting.

Warning that the use of specialty distributors may reduce the number of supply channels to only six locations and “compromise the entire nation’s ability to source these important drugs,” the letter calls upon Genentech to allow hospitals to “focus on providing the best care for their cancer patients.”

Joining the AAMC in signing the letter were: America’s Essential Hospitals; American Hospital Association; Catholic Health Association of the United States; Children’s Hospital Association; and Federation of American Hospitals.

Contact:

Christiane Mitchell
Senior Director Health Care Affairs
Telephone: 202-828-0461
Email: cmitchell@aamc.org

.

envelope on a green background

Subscribe to Washington Highlights

RSS icon

Subscribe to RSS

Washington Highlights, a weekly electronic newsletter, features brief updates on the latest legislative and regulatory activities affecting medical schools and teaching hospitals.


Past Issues


For More Information

Jason Kleinman
Sr. Legislative Analyst, Govt. Relations
Telephone: 202-903-0806
Email: jkleinman@aamc.org